Markets:

Overview

News

Currencies

International

Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

85.15 -3.12 (-3.53%)

Streaming Delayed Price Updated: 12:51 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 17, 2024

Via Benzinga

Inari Medical Stock Gets RS Rating Upgrade ↗

December 11, 2024

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.

Via Investor's Business Daily

Novocure Stock Earns 96 RS Rating ↗

December 03, 2024

On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.

Via Investor's Business Daily

ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year ↗

November 18, 2024

ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.

Via Investor's Business Daily

Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 01, 2024

Via Benzinga

In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular ↗

November 01, 2024

Via Benzinga

Analyst Scoreboard: 4 Ratings For LeMaitre Vascular ↗

October 15, 2024

Via Benzinga

Navigating 4 Analyst Ratings For LeMaitre Vascular ↗

May 31, 2024

Via Benzinga

This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 15, 2024

Via Benzinga

LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q2 2024 ↗

August 01, 2024

LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Staar Surgical Stock Earns RS Rating Upgrade ↗

June 27, 2024

On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77.

Via Investor's Business Daily

Stryker Stock Sees RS Rating Treks Higher To 71 ↗

May 29, 2024

Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71.

Via Investor's Business Daily

Sell In May And Go Away? – April Dividend Income Report ↗

May 27, 2024

The “Sell in May and Go Away” adage is wrong for most investors.

Via Talk Markets

LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Recap: LeMaitre Vascular Q4 Earnings ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

A Preview Of LeMaitre Vascular's Earnings ↗

February 26, 2024

Via Benzinga

Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78 ↗

April 30, 2024

On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78.

Via Investor's Business Daily

Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know ↗

February 28, 2024

Via Benzinga

Sidoti Events, LLC's Virtual December Small-Cap Conference

December 05, 2023

Via ACCESSWIRE

5 Analysts Have This to Say About LeMaitre Vascular ↗

October 23, 2023

Via Benzinga

Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating ↗

September 06, 2023

Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Looking for Dividend Growth? Buy This Little-Known Healthcare Stock ↗

September 01, 2023

The healthcare company's dividend has soared in recent years.

Via The Motley Fool

2 Healthcare Stocks That Could Help Make You a Fortune ↗

August 26, 2023

These companies did well for shareholders over the last 10 years and have the potential to keep the growth going.

Via The Motley Fool

Boston Scientific Stock Gets 81 RS Rating After Profit Pops 56% In Year ↗

August 23, 2023

Boston Scientific stock rose from a 34.98 low on June 16, 2022, amid the bear market, to an all-time high 54.66 close on June 22 this year.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023 ↗

August 03, 2023

Via Benzinga

Yum! Brands To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗

August 03, 2023

Needham raised the price target for Extreme Networks, Inc. (NASDAQ: EXTR) from $30 to $35. Needham analyst Alex Henderson maintained a Buy rating. Extreme Networks shares fell 1.7% to $29.70 in...

Via Benzinga

3 Micro-Cap Stocks to Buy Now for Gigantic Growth Potential ↗

June 28, 2023

The smallest stocks have been trailing their larger counterparts. Here are three top micro-cap stocks to ride the asset class' resurgence.

Via InvestorPlace

Beat the Dow Jones With This Unstoppable Dividend Stock ↗

June 19, 2023

The wealth created by this medical devices company for its investors over the past decade far exceeds what the Dow Jones generated.

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.